167 related articles for article (PubMed ID: 33423554)
1. SARS-CoV-2 protein drug targets landscape: a potential pharmacological insight view for the new drug development.
Chakraborty C; Bhattacharya M; Mallick B; Sharma AR; Lee SS; Agoramoorthy G
Expert Rev Clin Pharmacol; 2021 Feb; 14(2):225-238. PubMed ID: 33423554
[No Abstract] [Full Text] [Related]
2. Targeted therapy strategies against SARS-CoV-2 cell entry mechanisms: A systematic review of in vitro and in vivo studies.
Seyedpour S; Khodaei B; Loghman AH; Seyedpour N; Kisomi MF; Balibegloo M; Nezamabadi SS; Gholami B; Saghazadeh A; Rezaei N
J Cell Physiol; 2021 Apr; 236(4):2364-2392. PubMed ID: 32901936
[TBL] [Abstract][Full Text] [Related]
3. Simultaneous Inhibition of SARS-CoV-2 Entry Pathways by Cyclosporine.
Prasad K; Ahamad S; Kanipakam H; Gupta D; Kumar V
ACS Chem Neurosci; 2021 Mar; 12(5):930-944. PubMed ID: 33606519
[TBL] [Abstract][Full Text] [Related]
4. An Overview of SARS-CoV-2 Potential Targets, Inhibitors, and Computational Insights to Enrich the Promising Treatment Strategies.
Kumawat P; Agarwal LK; Sharma K
Curr Microbiol; 2024 May; 81(7):169. PubMed ID: 38733424
[TBL] [Abstract][Full Text] [Related]
5. Potential inhibitors of SARS-CoV-2: recent advances.
Jamalipour Soufi G; Iravani S
J Drug Target; 2021 Apr; 29(4):349-364. PubMed ID: 33210953
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of S-protein RBD and hACE2 Interaction for Control of SARSCoV- 2 Infection (COVID-19).
Nayak SK
Mini Rev Med Chem; 2021; 21(6):689-703. PubMed ID: 33208074
[TBL] [Abstract][Full Text] [Related]
7. TMPRSS2 and RNA-Dependent RNA Polymerase Are Effective Targets of Therapeutic Intervention for Treatment of COVID-19 Caused by SARS-CoV-2 Variants (B.1.1.7 and B.1.351).
Lee J; Lee J; Kim HJ; Ko M; Jee Y; Kim S
Microbiol Spectr; 2021 Sep; 9(1):e0047221. PubMed ID: 34378968
[TBL] [Abstract][Full Text] [Related]
8. SARS-CoV-2 entry inhibitors by dual targeting TMPRSS2 and ACE2: An in silico drug repurposing study.
Baby K; Maity S; Mehta CH; Suresh A; Nayak UY; Nayak Y
Eur J Pharmacol; 2021 Apr; 896():173922. PubMed ID: 33539819
[TBL] [Abstract][Full Text] [Related]
9. Insights into SARS-CoV-2: Medicinal Chemistry Approaches to Combat Its Structural and Functional Biology.
Zhuo LS; Wang MS; Yang JF; Xu HC; Huang W; Shang LQ; Yang GF
Top Curr Chem (Cham); 2021 Apr; 379(3):23. PubMed ID: 33886017
[TBL] [Abstract][Full Text] [Related]
10. Identification of FDA approved drugs against SARS-CoV-2 RNA dependent RNA polymerase (RdRp) and 3-chymotrypsin-like protease (3CLpro), drug repurposing approach.
Molavi Z; Razi S; Mirmotalebisohi SA; Adibi A; Sameni M; Karami F; Niazi V; Niknam Z; Aliashrafi M; Taheri M; Ghafouri-Fard S; Jeibouei S; Mahdian S; Zali H; Ranjbar MM; Yazdani M
Biomed Pharmacother; 2021 Jun; 138():111544. PubMed ID: 34311539
[TBL] [Abstract][Full Text] [Related]
11. An Updated Review on Betacoronavirus Viral Entry Inhibitors: Learning from Past Discoveries to Advance COVID-19 Drug Discovery.
Sabbah DA; Hajjo R; Bardaweel SK; Zhong HA
Curr Top Med Chem; 2021; 21(7):571-596. PubMed ID: 33463470
[TBL] [Abstract][Full Text] [Related]
12. Analysis of the SARS-CoV-2-host protein interaction network reveals new biology and drug candidates: focus on the spike surface glycoprotein and RNA polymerase.
Sokullu E; Pinard M; Gauthier MS; Coulombe B
Expert Opin Drug Discov; 2021 Aug; 16(8):881-895. PubMed ID: 33769912
[No Abstract] [Full Text] [Related]
13. Understanding Severe Acute Respiratory Syndrome Coronavirus 2 Replication to Design Efficient Drug Combination Therapies.
Ortega JT; Zambrano JL; Jastrzebska B; Liprandi F; Rangel HR; Pujol FH
Intervirology; 2020; 63(1-6):2-9. PubMed ID: 33099545
[TBL] [Abstract][Full Text] [Related]
14. Target identification for repurposed drugs active against SARS-CoV-2 via high-throughput inverse docking.
Ribone SR; Paz SA; Abrams CF; Villarreal MA
J Comput Aided Mol Des; 2022 Jan; 36(1):25-37. PubMed ID: 34825285
[TBL] [Abstract][Full Text] [Related]
15. Human endeavor for anti-SARS-CoV-2 pharmacotherapy: A major strategy to fight the pandemic.
Wang R; Stephen P; Tao Y; Zhang W; Lin SX
Biomed Pharmacother; 2021 May; 137():111232. PubMed ID: 33486202
[TBL] [Abstract][Full Text] [Related]
16. Reactive Centre Loop Mutagenesis of SerpinB3 to Target TMPRSS2 and Furin: Inhibition of SARS-CoV-2 Cell Entry and Replication.
Singh S; O'Reilly S; Gewaid H; Bowie AG; Gautier V; Worrall DM
Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293378
[TBL] [Abstract][Full Text] [Related]
17. Withanone from
Balkrishna A; Pokhrel S; Singh H; Joshi M; Mulay VP; Haldar S; Varshney A
Drug Des Devel Ther; 2021; 15():1111-1133. PubMed ID: 33737804
[TBL] [Abstract][Full Text] [Related]
18. Role of Structural and Non-Structural Proteins and Therapeutic Targets of SARS-CoV-2 for COVID-19.
Yadav R; Chaudhary JK; Jain N; Chaudhary PK; Khanra S; Dhamija P; Sharma A; Kumar A; Handu S
Cells; 2021 Apr; 10(4):. PubMed ID: 33917481
[TBL] [Abstract][Full Text] [Related]
19. Can Host Cell Proteins Like ACE2, ADAM17, TMPRSS2, Androgen Receptor be the Efficient Targets in SARS-CoV-2 Infection?
Gupta VK; Murthy MK; Patil S
Curr Drug Targets; 2021; 22(10):1149-1157. PubMed ID: 33243116
[TBL] [Abstract][Full Text] [Related]
20. An overview of the anti-SARS-CoV-2 properties of Artemisia annua, its antiviral action, protein-associated mechanisms, and repurposing for COVID-19 treatment.
Fuzimoto AD
J Integr Med; 2021 Sep; 19(5):375-388. PubMed ID: 34479848
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
